Summary of Key Points
Xianbo Biotech has recently completed a $400 million Series B financing, which will be used to advance two core cell therapy products: the first is the universal CAR-NK product SNC103 (targeting lupus erythematosus, with positive Phase I clinical results, aiming to become the world's first approved universal CAR-NK therapy), and the second is the registration clinical trial for the in vivo CAR-T platform SNC116. This reflects a transformation trend in the cell therapy industry – moving from high-cost, customized autologous CAR-T therapies to more affordable, off-the-shelf technologies to address issues such as high prices and high risks. At the same time, autoimmune diseases are becoming a new focus for cell therapy, and financing in the field of cell and gene therapy (CGT) has seen a resurgence in the first half of 2026.
Detailed Analysis
1. Where Will the $400 Million Be Invested? Betting on Two “Next-Generation” Cell Therapies
Xianbo Biotech’s funds will be primarily allocated to two key projects:
- SNC103 (Universal CAR-NK): This is a modified form of immune cells (NK cells) that can accurately identify and attack cells marked with CD19, which are key targets in autoimmune diseases like lupus erythematosus. The highlight of SNC103 is its universality; it does not require the use of the patient's own cells but can be mass-produced using cells from healthy donors, providing a “off-the-shelf” supply similar to conventional drugs. The Phase I clinical trials for lupus erythematosus have been promising, and the company plans to initiate registration clinical trials in 2027, with the goal of becoming the world’s first approved universal CAR-NK product.
- SNC116 (In Vivo CAR-T): Traditional CAR-T therapies involve extracting the patient’s T cells, modifying them, and then reinfusing them into the body. In contrast, in vivo CAR-T uses a viral vector to directly modify the T cells within the patient’s body, making the process simpler and less costly. Xianbo Biotech aims to advance the registration clinical trials for SNC116 to accelerate its commercialization.
In short, both SNC103 and SNC116 represent “cheaper and more convenient” cell therapies, and investors are betting that they can overcome the limitations of existing technologies.
2. Why Are Universal CAR-NK Therapies Such a Hot Topic for Investors? The Challenges of Autologous CAR-T
Autologous CAR-T therapies are currently the mainstream in cell therapy, but they face significant challenges:
- Exorbitant Costs: These therapies are custom-made for each patient, involving complex and time-consuming procedures such as blood collection, T cell extraction, modification, and reinfusion, resulting in extremely high costs. Autologous CAR-T products already on the market in China cost millions of yuan, making them unaffordable for most families.
- High Risks: Before reinfusion, patients must undergo chemotherapy to reduce their immune system, which can lead to decreased immunity, increased susceptibility to infections, and complications such as anemia and thrombocytopenia.
Universal CAR-NK therapies address these issues by reducing costs (Xianbo Biotech claims that SNC103’s costs can be brought down to the level of conventional biopharmaceuticals, possibly in the range of several thousand to tens of thousands of yuan). They also do not require the use of the patient’s own cells or pre-chemotherapy, significantly lowering the risks. This is the core reason why investors are interested in these therapies – they have the potential to make cell therapy more accessible to a broader audience.
3. The Transformation of the Cell Therapy Industry: From “Customized Medications” to “Off-the-Shelf Drugs”
The cell therapy industry is shifting from a focus on customized treatments to standardized, mass-produced drugs:
- Autologous CAR-T: Similar to custom-made suits, these are expensive and time-consuming.
- Universal/Off-the-Shelf Therapies: These are mass-produced, cheaper, and readily available.
- In Vivo Editing Technologies: More advanced approaches directly modify cells within the patient’s body, eliminating the need for cell extraction altogether.
The goal of this transformation is to break down the barriers of “one patient, one therapy” and make cell therapy as accessible as antibiotics and vaccines, becoming a widely available and affordable treatment option. Xianbo Biotech’s financing reflects this trend, as investors believe that universal technologies will make cell therapy more accessible to the general public.
4. Cell Therapy Beyond Cancer: Autoimmune Diseases as a New Frontier
While cell therapy has traditionally focused on cancer (such as leukemia), autoimmune diseases (like lupus erythematosus and rheumatoid arthritis) are now becoming a new area of focus:
- Autoimmune diseases involve the immune system attacking the body’s own tissues, and traditional treatments (such as steroids and immunosuppressants) only provide symptomatic relief.
- Cell therapy can target the root causes by adjusting the immune system; for example, SNC103 attacks CD19-positive B cells to reduce the production of autoantibodies, thereby treating lupus erythematosus.
- Previously, progress in cell therapy for autoimmune diseases was hindered by high costs and supply issues, but the development of universal technologies has overcome these challenges, leading to increasing interest in this field.
Xianbo Biotech’s SNC103 is a representative of this trend, offering a more effective and commercially viable approach for treating lupus erythematosus.
5. The Revival of CGT Financing: Industry Confidence Is Backing Up
The financing situation in the cell and gene therapy (CGT) sector reflects the industry’s momentum:
- 2021 was a peak year, but funding declined in 2022 due to the economic environment.
- Funding began to recover in 2025, reaching $836 million in the first half of 2026, nearly matching the annual total of 2025.
The reason for this revival is the progress of universal and in vivo editing technologies, which have shown potential for commercial success. Previously, CGT was seen as a costly research and development endeavor, but with the emergence of viable products (such as universal CAR-NK), investors are once again investing in the sector. Xianbo Biotech’s financing is a testament to this trend.
Conclusion
Xianbo Biotech’s financing is not an isolated event; it signals a transformation in the cell therapy industry from high-cost, customized treatments to affordable, universal therapies. Universal technologies have addressed the issues of high costs and risks, making cell therapy more accessible to a broader range of patients. The new focus on autoimmune diseases opens up significant market opportunities, and the resurgence in financing indicates that investors are gaining confidence in the industry. In the future, cell therapy may no longer be an exclusive luxury but could become as common as conventional medicines.